IQVIA艾昆纬：2025年心脏代谢领域创新商业化的卓越实践白皮书：挑战及策略（英文版）

Cardiometabolic diseases remain among the leading causes of mortality and morbidity globally, collectively accounting for over one third of all global deaths and impacting health-related quality of life by an estimated 500 million Disability-Adjusted Life Years (DALYs).2-4 One of the defining features of cardiometabolic diseases is the substantial overlap between different patient populations, because many indications manifest themselves as co-morbidities in the same patient (see Figure 1): S